Drug Search Results
More Filters [+]

Nilvadipine

Alternative Names: nilvadipine
Latest Update: 2024-04-15
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: Calcium Channel Blocker

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Austria | Brazil | Chile | Colombia | Finland | Germany | Ireland | Italy | Peru | Portugal | Venezuela

Approved Indications: None

Known Adverse Events: None

Company: University of Sydney
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Nilvadipine

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 4: Alzheimer Disease

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

A Trial of Nilvadipine in Mild to Moderate Alzheimer's disease

P3

Completed

Alzheimer Disease

2016-12-16

NILVAD

P3

Completed

Alzheimer Disease

2016-12-16

St. James's Hospital Nivadil Trial

P4

Completed

Alzheimer Disease

2009-03-03

Recent News Events